Drug Profile
Monoclonal antibody ERIC-1
Alternative Names: ERIC-1Latest Information Update: 29 Aug 2001
Price :
$50
*
At a glance
- Originator Imperial Cancer Research Technology
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 29 Aug 2001 No-Development-Reported for Glioma in United Kingdom (Unknown route)
- 28 Jul 1998 ERIC-1 is now called monoclonal antibody ERIC-1
- 02 Feb 1995 Phase-I clinical trials for Glioma in United Kingdom (Unknown route)